Grace Karafa Obermann
33 IP cases indexed. Covers patent matters.
Cases Presided Over
33 cases indexed | Page 1 of 2
Samsung Display Co., Ltd. et al. v.Pictiva Displays International Limited et al.
The PTAB issued a Final Written Decision finding all of Samsung's challenged OLED claims unpatentable. The Board held that the claims were obvious over multiple prior‑art OLED references. The decision affirms the institution of the IPR.
WHOOP, Inc. v.Omni MedSci, Inc.
In a Final Written Decision, the PTAB held that WHOOP proved 12 of the 23 challenged claims of Omni MedSci’s wearable physiological‑monitoring patent unpatentable, while the remaining claims were left intact.
WHOOP, Inc. v.Omni MedSci, Inc.
Apple’s IPR against Omni MedSci’s wearable physiological monitoring patent resulted in the Board finding all challenged claims unpatentable as obvious over Lisogurski, Carlson, and Mannheimer references.
WHOOP, Inc. v.Omni MedSci, Inc.
The PTAB, on remand, affirmed that all 23 claims of Omni MedSci’s wearable pulse‑oximeter patent are unpatentable. The Board relied on obviousness over a combination of prior‑art references and upheld the claim construction of “identify an object.”
WHOOP, Inc. v.Omni MedSci, Inc.
The PTAB held that all challenged claims of the ’533 wearable physiological measurement patent were unpatentable as obvious over Lisogurski, Carlson, and Mannheimer references.
WHOOP, Inc. v.Omni MedSci, Inc.
The PTAB held that WHOOP’s challenge to Omni MedSci’s 9,651,533 patent failed; all asserted claims were found obvious over Lisogurski, Carlson, and Mannheimer under §103(a).
WHOOP, Inc. v.Omni MedSci, Inc.
The PTAB affirmed the construction of “identify an object” and held that all 23 claims of WHOOP’s wearable health‑monitoring patent are obvious over a combination of prior‑art references, rendering them unpatentable.
WHOOP, Inc. v.Omni MedSci, Inc.
The PTAB remand decision held that all 23 claims of Omni MedSci’s wearable pulse‑oximetry patent are unpatentable, applying 35 U.S.C. § 103 obviousness over multiple prior‑art references.
WHOOP, Inc. v.Omni MedSci, Inc.
Apple’s IPR against WHOOP resulted in the Board finding all 23 claims of the wearable health‑monitoring patent unpatentable under obviousness. The decision affirmed the petitioner’s claim construction and rejected the patent owner’s arguments.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple succeeded in invalidating Omni MedSci's wearable physiological measurement patent, with the PTAB finding all challenged claims obvious over prior art.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple prevailed in an IPR against Omni MedSci’s wearable health‑monitoring patent, finding claims 1, 2, 7 and 15‑23 unpatentable while leaving claims 3‑6 and 8‑14 intact.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s IPR of Omni MedSci’s 9,651,533 patent was decided with all challenged claims found unpatentable under §103, based on obviousness over Lisogurski, Carlson, and Mannheimer prior art.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s IPR against Omni MedSci’s ‘299 patent was decided with all challenged claims (7, 10‑14) found unpatentable as obvious over Lisogurski, Carlson, Mannheimer, and Park references.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple successfully invalidated Omni MedSci’s wearable pulse‑oximeter patent in a final PTAB decision, finding all 23 claims unpatentable for obviousness. The Board affirmed claim constructions and applied the petitioner’s alternative argument on the combination of prior‑art references.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple successfully challenged Omni MedSci’s wearable health‑monitoring patent. The PTAB affirmed the claim construction and held all 23 claims obvious over prior art. No further briefing was authorized.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
The PTAB held that Apple’s wearable physiological measurement claims were obvious over prior‑art pulse‑oximetry references, rendering all challenged claims unpatentable. The decision relied on Lisogurski, Carlson, and Mannheimer teachings.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s IPR resulted in the Board finding all six challenged claims of Omni MedSci’s ’299 patent unpatentable as obvious over a combination of prior‑art references covering wearable optical sensing.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
The PTAB issued a Final Written Decision in IPR2021‑00453, finding claims 1,2,7 and 15‑23 of Omni MedSci’s wearable pulse‑oximeter patent unpatentable over prior art, while leaving the remaining claims intact.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s IPR against Omni MedSci’s wearable physiological measurement patent resulted in all challenged claims being held unpatentable. The Board found the claims obvious over Lisogurski, Carlson, and Mannheimer under §103(a).
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s inter‑partes review of Omni MedSci’s ’533 patent resulted in the PTAB finding all challenged claims unpatentable for obviousness over Lisogurski, Carlson, and Mannheimer.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s IPR against Omni MedSci’s wearable health‑monitoring patent resulted in the Board finding all challenged claims unpatentable as obvious over a combination of prior‑art references.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple (as petitioner) secured a Final Written Decision finding claims 1,2,7,15‑23 of Omni MedSci’s wearable health‑monitoring patent unpatentable as obvious over prior‑art. The Board affirmed the petitioner's obviousness arguments while leaving claims 3‑6 and 8‑14 intact.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s petition succeeded; the PTAB held all challenged claims of Omni MedSci’s wearable physiological measurement patent unpatentable as obvious over Lisogurski, Carlson, and Mannheimer references.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
The PTAB issued a Final Written Decision on remand, holding that all 23 claims of Omni MedSci’s wearable pulse‑oximeter patent are unpatentable. The Board relied on an obviousness analysis over a combination of prior‑art references and affirmed the claim construction of “identify an object.”
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
The PTAB held that Samsung’s challenge to Omni MedSci’s wearable physiological monitoring patent succeeded on 12 of the 23 claims, finding them obvious over prior‑art references such as Lisogurski, Carlson, Tran, Isaacson and Valencell‑093. The remaining claims were not shown unpatentable.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s IPR against Omni MedSci’s ‘533 patent resulted in all challenged claims being found unpatentable. The Board held that the claims were obvious over prior‑art references Lisogurski, Carlson, and Mannheimer.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple prevailed in an IPR against Omni MedSci’s wearable health‑monitoring patent, finding 12 of the 23 claims unpatentable while the remaining claims survived.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple (as petitioner) prevailed in an IPR against Omni MedSci’s 9,651,533 patent, with the PTAB finding all challenged claims unpatentable as obvious over Lisogurski, Carlson, and Mannheimer. The decision hinges on pulse‑rate and signal‑to‑noise teachings in the prior art.
ClearCorrect Operating, LLC et al. v.Align Technology, Inc.
The PTAB affirmed Align Technology’s patent on a dual‑shell dental sheet composition, finding none of the challenged claims unpatentable after a detailed obviousness analysis involving Hinz, Durasoft data sheets, and Sun.
ClearCorrect Operating, LLC et al. v.Align Technology, Inc.
The PTAB affirmed all claims of Align Technology’s ‘630 patent after finding ClearCorrect’s obviousness arguments unpersuasive. No claim was deemed unpatentable.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.